GPX4 and cancer: ML210 used in this study was developed as a more selective GPX4 inhibitor with improved physiochemical and pharmacokinetic properties [47], but there are no reports using ML210 treatments in in vivo cancer models and the in vivo efficacy and toxicity remain unknown.